Please assess the completion status of the following clinical trial:

Trial Title: Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary PAP (new or chronic) with presence of anti-GM-CSF antibody~* Moderately symptomatic disease with PaO2 \<70 on room air and on less than 6 L/min oxygen~* Able to give written informed consent and comply with the requirements of the study~* Adequate renal and liver function~* Negative serum pregnancy test (for women of child bearing age) and on acceptable birth control during and after study completion~Exclusion Criteria:~* Severe PAP and requires in-patient care and more urgent therapy with bilateral whole lung lavage~* Treatment with any investigational agent within 4 weeks of screening~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies~* History of HIV, recurrent significant infection or recurrent bacterial infections~* Known active bacterial, viral, fungal, mycobacterial, or other infection~* Ongoing use of high dose steroids (\>10mg/day) or unstable steroid dose~* Significant cardiac or pulmonary disease or blood disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).